MoveDMD: phase 2 trial of edasalonexent, an NF-κB...

Neuromuscular Disorders 2017 / 10 Vol. 27

MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dystrophy

Finkel, R., Vandenborne, K., Sweeney, H., Finanger, E., Tennekoon, G., Shieh, P., Willcocks, R., Forbes, S., Triplett, W., Yum, S., Mancini, M., Friedman, M., Fretzen, A., Donovan, J.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Language:
english
Journal:
Neuromuscular Disorders
DOI:
10.1016/j.nmd.2017.06.437
Date:
October, 2017
File:
PDF, 239 KB
english, 2017
Conversion to is in progress
Conversion to is failed